Abeona Therapeutics Inc.

File an Investigational New Drug application and commence first-in-human studies for ABO-701

Deadline not yet reached (430 days left)

Announced: 13 May 2026
Due: 31 Dec 2027

Deadline
Met
Late
Not met
Today

What the company said

“Abeona expects to file an Investigational New Drug (IND) application and commence first-in-human studies with ABO-701 in the second half of 2027”

SourceAbeona Therapeutics Inc. Form 8-K press release, 2026-05-13
FilingSEC filing index
Deadline as statedin the second half of 2027
Deadline used31 Dec 2027, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2026-ABEO-003407
Cite as https://keptindex.org/c/KI-C-2026-ABEO-003407/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory submission
Indicative materiality: High rules
Action: File
Deliverable: IND application and first-in-human studies for ABO-701
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High
Depends on: Regulatory

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Abeona Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-ABEO-003407 · Corrections policy